Checkpoint inhibitors: 'Raising the bar' also in brain metastases from non-small-cell lung cancer?

Sabrina Rossi, Giovanna Finocchiaro, Silvia Marchetti, Luca Toschi, Armando Santoro

Research output: Contribution to journalReview article

Abstract

Despite efforts, brain metastases (BM) remain a critical issue in the management of patients affected by non-small-cell lung cancer (NSCLC). To date, radiotherapy is still considered the gold standard treatment; on the other hand, systemic chemotherapeutical agents are not so often an effective therapy for BM, whereas targeted agents in oncogene-addicted disease have shown a good activity also on BM. Anti-programmed death-1/programmed death ligand-1 agents represent a new valid therapeutic strategy for NSCLC as well as for several tumor types, but their efficacy on patients with BM is still unclear mainly due to the strict selection criteria adopted in clinical trials. The aim of the present article is to discuss the potential activity of checkpoint inhibitors in patients with BM from NSCLC.

Original languageEnglish
Pages (from-to)403-410
Number of pages8
JournalImmunotherapy
Volume10
Issue number5
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Brain
Oncogenes
Patient Selection
Radiotherapy
Therapeutics
Clinical Trials
Ligands
Neoplasms

Keywords

  • brain metastases NSCLC
  • checkpoint inhibitors blood-brain barrier
  • immunotherapy blood-brain barrier

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Checkpoint inhibitors : 'Raising the bar' also in brain metastases from non-small-cell lung cancer? / Rossi, Sabrina; Finocchiaro, Giovanna; Marchetti, Silvia; Toschi, Luca; Santoro, Armando.

In: Immunotherapy, Vol. 10, No. 5, 01.04.2018, p. 403-410.

Research output: Contribution to journalReview article

@article{489ab8a3dc15430db97ee82e49a06363,
title = "Checkpoint inhibitors: 'Raising the bar' also in brain metastases from non-small-cell lung cancer?",
abstract = "Despite efforts, brain metastases (BM) remain a critical issue in the management of patients affected by non-small-cell lung cancer (NSCLC). To date, radiotherapy is still considered the gold standard treatment; on the other hand, systemic chemotherapeutical agents are not so often an effective therapy for BM, whereas targeted agents in oncogene-addicted disease have shown a good activity also on BM. Anti-programmed death-1/programmed death ligand-1 agents represent a new valid therapeutic strategy for NSCLC as well as for several tumor types, but their efficacy on patients with BM is still unclear mainly due to the strict selection criteria adopted in clinical trials. The aim of the present article is to discuss the potential activity of checkpoint inhibitors in patients with BM from NSCLC.",
keywords = "brain metastases NSCLC, checkpoint inhibitors blood-brain barrier, immunotherapy blood-brain barrier",
author = "Sabrina Rossi and Giovanna Finocchiaro and Silvia Marchetti and Luca Toschi and Armando Santoro",
year = "2018",
month = "4",
day = "1",
doi = "10.2217/imt-2017-0151",
language = "English",
volume = "10",
pages = "403--410",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Checkpoint inhibitors

T2 - 'Raising the bar' also in brain metastases from non-small-cell lung cancer?

AU - Rossi, Sabrina

AU - Finocchiaro, Giovanna

AU - Marchetti, Silvia

AU - Toschi, Luca

AU - Santoro, Armando

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Despite efforts, brain metastases (BM) remain a critical issue in the management of patients affected by non-small-cell lung cancer (NSCLC). To date, radiotherapy is still considered the gold standard treatment; on the other hand, systemic chemotherapeutical agents are not so often an effective therapy for BM, whereas targeted agents in oncogene-addicted disease have shown a good activity also on BM. Anti-programmed death-1/programmed death ligand-1 agents represent a new valid therapeutic strategy for NSCLC as well as for several tumor types, but their efficacy on patients with BM is still unclear mainly due to the strict selection criteria adopted in clinical trials. The aim of the present article is to discuss the potential activity of checkpoint inhibitors in patients with BM from NSCLC.

AB - Despite efforts, brain metastases (BM) remain a critical issue in the management of patients affected by non-small-cell lung cancer (NSCLC). To date, radiotherapy is still considered the gold standard treatment; on the other hand, systemic chemotherapeutical agents are not so often an effective therapy for BM, whereas targeted agents in oncogene-addicted disease have shown a good activity also on BM. Anti-programmed death-1/programmed death ligand-1 agents represent a new valid therapeutic strategy for NSCLC as well as for several tumor types, but their efficacy on patients with BM is still unclear mainly due to the strict selection criteria adopted in clinical trials. The aim of the present article is to discuss the potential activity of checkpoint inhibitors in patients with BM from NSCLC.

KW - brain metastases NSCLC

KW - checkpoint inhibitors blood-brain barrier

KW - immunotherapy blood-brain barrier

UR - http://www.scopus.com/inward/record.url?scp=85042671914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042671914&partnerID=8YFLogxK

U2 - 10.2217/imt-2017-0151

DO - 10.2217/imt-2017-0151

M3 - Review article

C2 - 29473467

AN - SCOPUS:85042671914

VL - 10

SP - 403

EP - 410

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 5

ER -